Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer and non-small cell lung cancer, as well as for liquid or solid tumors, appendiceal, colorectal and gastric cancers, other gynecologic malignancies, and peritoneal mesothelioma. The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California. Show more

Location: 2625 Townsgate Road, Westlake Village, CA, 91361, United States | Website: https://www.genelux.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

125M

52 Wk Range

$1.95 - $5.88

Previous Close

$3.31

Open

$3.31

Volume

96,555

Day Range

$3.30 - $3.60

Enterprise Value

98.76M

Cash

27.97M

Avg Qtr Burn

-5.636M

Insider Ownership

13.22%

Institutional Own.

19.38%

Qtr Updated

06/30/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Olvi-Vec (Olvimulogene nanivacirepvec) + platinum-doublet + bevacizumab Details Cancer, Platinum-resistant ovarian cancer, Ovarian cancer	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Olvi-Vec (Olvimulogene nanivacirepvec) Details Cancer, Non-small cell lung carcinoma	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Olvi-Vec (Olvimulogene nanivacirepvec) Details Cancer, Small cell lung cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.